Company Encyclopedia
View More
name
Avanos Medical
AVNS.US
Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; OrthogenRx knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions.
330.79 B
AVNS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care SuppliesIndustry
Industry Ranking18/42
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-46.68%E
    • Profit Margin-67.00%E
    • Gross Margin48.37%B
  • Growth ScoreD
    • Revenue YoY2.70%C
    • Net Profit YoY-3086.62%E
    • Total Assets YoY-35.53%E
    • Net Assets YoY-36.73%E
  • Cash ScoreD
    • Cash Flow Margin-149.26%D
    • OCF YoY2.70%C
  • Operating ScoreC
    • Turnover0.51C
  • Debt ScoreB
    • Gearing Ratio27.13%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Avanos Medical Amends Report to Disclose Full Vesting of Restricted Stock Units for Departed Executive

    Avanos Medical Inc. amended its Form 8-K to disclose that all 16,300 restricted stock units granted to Mojirade James vested fully on December 1, 2025, after her employment ended. Other disclosures remain unchanged.

    Reuters·
    US
    AVNS
    +1.17%
    Reuters·
    US
    AVNS
    +1.17%

    VP Holbrook Sells 15,000 ($165K) Of Avanos Medical Inc [AVNS]

    Holbrook Kerr Vice President of Avanos Medical Inc [AVNS] filed a Form 4 on November 19, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/18/25TransactionSaleShares15,000Price$11.00Value$165,014Ending Holdings: 83,860 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    AVNS
    +1.17%
    Reuters·
    US
    AVNS
    +1.17%

    Shareholder Holbrook Files To Sell 15,000 Of Avanos Medical Inc [AVNS]

    Holbrook Kerr, a shareholder of Avanos Medical Inc, filed a Form 144 with the SEC to sell 15,000 restricted shares on November 18, 2025. The sale will be conducted through Fidelity Brokerage Services. Form 144 is required for selling restricted stock, allowing sales within 90 days of filing. The Washington Service offers insider trading analysis and data services.

    Reuters·
    US
    AVNS
    +1.17%
    Reuters·
    US
    AVNS
    +1.17%

    Avanos Medical’s Earnings Call: Growth Amid Challenges

    Avanos Medical, Inc. held its Q3 earnings call, highlighting strong growth in the Specialty Nutrition Systems segment with a 10% rise in organic sales. The company successfully divested its hyaluronic acid business and acquired Nexus Medical, enhancing its market presence. Financially, Avanos reported net sales of $178 million and raised its full-year revenue guidance to $690-$700 million. However, challenges remain, including tariffs and flat growth in the Pain Management segment. The company anticipates $15-$20 million in annual cost savings by 2026, maintaining a positive outlook despite ongoing challenges.

    Tip Ranks·
    US
    AVNS
    +1.17%
    Tip Ranks·
    US
    AVNS
    +1.17%

    Avanos Medical | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 177.8 M

    LB filings·
    US
    AVNS
    +1.17%
    LB filings·
    US
    AVNS
    +1.17%
    © 2025 Longbridge｜Disclaimer